RecruitingNCT05938972

Real Life Study of Biologicals in Patients With Severe CRSwNP

Real Life Study Assessing Long Term Outcomes and Predictive Factors of Response to Biologicals in Patients With Severe CRSwNP and/or Severe Allergic and/or Eosinophilic Asthma

Sponsor

University Hospital, Ghent

Enrollment

180 participants

Start Date

Mar 1, 2022

Study Type

OBSERVATIONAL

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Summary

This study is a pragmatic, real-life, observational study recruiting adult patients with chronic rhinosinusitis with nasal polyposis who are eligible to start biologicals as standard treatment. The aim of this study is to observe the long-term outcomes of biologicals in CRSwNP patients with or without comorbid asthma in 'real life'. Moreover, the investigators will gain insight into the mechanisms of biologicals in the local and systemic immunity of these patients and investigate novel local and systemic biomarkers and predictors of response.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This real-world study is monitoring patients with severe chronic rhinosinusitis with nasal polyps (a condition where growths form inside the nose and sinuses, causing serious congestion and breathing problems) who are being treated with biologic medications (targeted injections). **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with severe chronic rhinosinusitis with nasal polyps (CRSwNP) - You are starting or already receiving a biologic treatment for this condition - You are able to comply with the study follow-up schedule **You may NOT be eligible if...** - You do not have a confirmed diagnosis of CRSwNP - You are unable or unwilling to comply with the protocol - You have contraindications to biologic therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMepolizumab

Monoclonal antibodies

Locations(1)

Ghent University Hospital

Ghent, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05938972

Related Trials

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347121 locations

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study

NCT0691490824 locations

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360113 locations

A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients

NCT0744673810 locations

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT0670681745 locations